Evidence map›Paper›PMID 39960210›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2025

The IRF2-INPP4B Pathway Aggravates Acute Myeloid Leukemia

Xiangqin Xing, Mei Zhang, Shengfen Tan, Junfeng Zhu, Jiajia Li, Pingping Zhang, Yuan Yuan, Meng Wang, Feng Zhang

Abstract read
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiangqin XingBengbu Medical University, Department of Hematology, Bengbu, P.R. China
Mei ZhangBengbu Medical University, Department of Hematology, Bengbu, P.R. ChinaORCID 0009-0001-5798-8705
Shengfen TanBengbu Medical University, Department of Hematology, Bengbu, P.R. ChinaORCID 0009-0007-6639-6983
Junfeng ZhuThe First Affiliated Hospital of Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
Jiajia LiThe First Affiliated Hospital of Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
Pingping ZhangThe First Affiliated Hospital of Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
Yuan YuanThe First Affiliated Hospital of Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
Meng WangBengbu Medical University, Department of Hematology, Bengbu, P.R. China
Feng ZhangBengbu Medical University, Department of Hematology, Bengbu, P.R. ChinaORCID 0009-0001-3286-9590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Interferon-regulatory factor 2 (IRF2) and inositol polyphosphate 4-phosphatase B (INPP4B) are indispensable for differentiating immune T-cells, but the regulatory principle of the IRF2-INPP4B signaling channel in the apoptosis of acute myeloid leukemia (AML) cells remains unclear. This work investigates the function and regulatory principle of IRF2-INPP4B signaling in the progression of AML. Materials and Methods: CD4 Results: We discovered that levels of IRF2 and INPP4B were high in AML-derived CD4 Conclusion: We revealed that IRF2-INPP4B signaling in CD4

Indexed as

Interferon Regulatory Factor-2Leukemia, Myeloid, AcutePhosphoric Monoester HydrolasesSignal TransductionAdultApoptosisCD4-Positive T-LymphocytesFemaleHL-60 CellsHumansJanus Kinase 2MaleMiddle AgedInterferon Regulatory Factor-2IRF2 protein, humanJanus Kinase 2phosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphoric Monoester HydrolasesAcute myeloid leukemiaApoptosisIRF2-INPP4BJAK2-STAT3 signaling channel

Identifiers

PMID39960210
PMCPMC12099465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.